CN114601920A - 一种用于改善骨关节健康的口服脂质体组合物及其制备方法 - Google Patents
一种用于改善骨关节健康的口服脂质体组合物及其制备方法 Download PDFInfo
- Publication number
- CN114601920A CN114601920A CN202210293733.3A CN202210293733A CN114601920A CN 114601920 A CN114601920 A CN 114601920A CN 202210293733 A CN202210293733 A CN 202210293733A CN 114601920 A CN114601920 A CN 114601920A
- Authority
- CN
- China
- Prior art keywords
- temperature
- parts
- bone joint
- oral
- joint health
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 27
- 230000037231 joint health Effects 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title abstract description 18
- 239000000284 extract Substances 0.000 claims abstract description 41
- 240000007817 Olea europaea Species 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 23
- 241000209140 Triticum Species 0.000 claims abstract description 22
- 235000021307 Triticum Nutrition 0.000 claims abstract description 22
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 20
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 18
- 210000000845 cartilage Anatomy 0.000 claims abstract description 13
- 102000008186 Collagen Human genes 0.000 claims abstract description 12
- 108010035532 Collagen Proteins 0.000 claims abstract description 12
- 229920001436 collagen Polymers 0.000 claims abstract description 12
- 239000008347 soybean phospholipid Substances 0.000 claims abstract description 12
- 241000237502 Ostreidae Species 0.000 claims abstract description 11
- 235000020636 oyster Nutrition 0.000 claims abstract description 11
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 10
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 7
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 7
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims abstract description 4
- 239000000463 material Substances 0.000 claims abstract description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 29
- 238000001694 spray drying Methods 0.000 claims description 27
- 239000000706 filtrate Substances 0.000 claims description 24
- 238000010438 heat treatment Methods 0.000 claims description 21
- 238000001556 precipitation Methods 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- 238000005516 engineering process Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 13
- 238000005342 ion exchange Methods 0.000 claims description 12
- 238000005374 membrane filtration Methods 0.000 claims description 12
- 238000009835 boiling Methods 0.000 claims description 11
- 239000008213 purified water Substances 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 239000006185 dispersion Substances 0.000 claims description 10
- 239000002243 precursor Substances 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 9
- 102000004142 Trypsin Human genes 0.000 claims description 6
- 108090000631 Trypsin Proteins 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 6
- 230000009849 deactivation Effects 0.000 claims description 6
- 238000011033 desalting Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 230000003301 hydrolyzing effect Effects 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 6
- 230000007935 neutral effect Effects 0.000 claims description 6
- 239000012588 trypsin Substances 0.000 claims description 6
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 6
- 239000012498 ultrapure water Substances 0.000 claims description 6
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 6
- 241000857907 Chimonanthus salicifolius Species 0.000 claims description 5
- 241000233779 Cyclocarya paliurus Species 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000002002 slurry Substances 0.000 claims description 5
- 240000003915 Lophatherum gracile Species 0.000 claims description 4
- 241000180649 Panax notoginseng Species 0.000 claims description 4
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 108091005658 Basic proteases Proteins 0.000 claims description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 235000011869 dried fruits Nutrition 0.000 claims description 3
- 238000004537 pulping Methods 0.000 claims description 3
- 239000013557 residual solvent Substances 0.000 claims description 3
- 238000003809 water extraction Methods 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 238000007599 discharging Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000012676 herbal extract Substances 0.000 claims description 2
- 235000014214 soft drink Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000001276 controlling effect Effects 0.000 claims 6
- 230000001105 regulatory effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 17
- 230000008901 benefit Effects 0.000 abstract description 9
- 201000008482 osteoarthritis Diseases 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 3
- 239000000796 flavoring agent Substances 0.000 abstract description 2
- 235000019634 flavors Nutrition 0.000 abstract description 2
- 235000019629 palatability Nutrition 0.000 abstract description 2
- 239000000049 pigment Substances 0.000 abstract description 2
- 239000003755 preservative agent Substances 0.000 abstract description 2
- 230000000717 retained effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 32
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 11
- 102000000503 Collagen Type II Human genes 0.000 description 10
- 108010041390 Collagen Type II Proteins 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 208000006820 Arthralgia Diseases 0.000 description 6
- 210000000629 knee joint Anatomy 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 3
- 229920001287 Chondroitin sulfate Polymers 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229940059329 chondroitin sulfate Drugs 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- -1 reverse evaporation Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- 235000003717 Boswellia sacra Nutrition 0.000 description 2
- 240000007551 Boswellia serrata Species 0.000 description 2
- 235000012035 Boswellia serrata Nutrition 0.000 description 2
- 244000163122 Curcuma domestica Species 0.000 description 2
- 235000003392 Curcuma domestica Nutrition 0.000 description 2
- 235000016623 Fragaria vesca Nutrition 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 2
- 239000004863 Frankincense Substances 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 206010023232 Joint swelling Diseases 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 206010057178 Osteoarthropathies Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 235000013976 turmeric Nutrition 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- 244000298697 Actinidia deliciosa Species 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241000548230 Crassostrea angulata Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 230000002648 chondrogenic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229960002849 glucosamine sulfate Drugs 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 244000237330 gutta percha tree Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229940095066 hydroxytyrosol Drugs 0.000 description 1
- 235000003248 hydroxytyrosol Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010010 raising Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Physiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及一种用于改善骨关节健康的口服脂质体组合物以及制备方法,包括以下质量份数的组分:非变性II型胶原蛋白1~10份,软骨胶原蛋白肽10~50份,小麦低聚肽1~10份,中药提取物5~20份,橄榄果提取物1~10份,牡蛎低聚肽5~10份,透明质酸钠1~10份,植物甾醇1~10份,大豆磷脂1~10份。本发明中各种组分合理搭配、适口性好,不添加防腐剂、人工色素、合成香精香料,药食同源,具有良好的改善骨关节健康的功效,且本发明的制备方法最大程度地保留了药物、食材的主要功效成分,服用量显著下降的同时也极大地提高了药物的生物利用度,患者依从性好,达到快速改善骨关节炎症状的目的。
Description
技术领域
本发明涉及生物技术领域,尤其涉及一种用于改善骨关节健康的口服脂质体组合物及其制备方法。
背景技术
骨关节炎(osteoarthritis,OA)是以关节软骨的变性破坏及骨化生为特点的慢性关节疾病,又称骨关节病、退行性骨关节病。骨关节炎会影响全身大部分关节,例如:颈腰椎、膝关节、髋关节和指间关节等骨关节炎,是一种逐渐进展加重性的疾病。目前对骨关节炎的治疗以延缓病情发展,减轻疼痛和改善关节功能为目的。
目前改善骨关节健康常用的膳食补充剂有氨基葡萄糖、硫酸软骨素、乳香、姜黄和鱼油等,但是这些膳食补充剂都存在一定局限性:对氨基葡萄糖和硫酸软骨素改善OA 效果存在争议;乳香会引起肠道不适;姜黄生物利用率低;鱼油有不耐受和腹泻问题等。上世纪90年代,非变性II型胶原蛋白用于治疗类风湿性关节炎,此后又开展了关于非变性II型胶原蛋白改善骨关节健康的研究,研究结果表明非变性Ⅱ型胶原蛋白具有方便、安全无毒及抗原特性等优点,将会成为预防和改善关节炎的革命性功能原料。因此,研究并开发具有改善骨关节健康功能的产品,对提高我国人民健康水平、对健康中国建设具有极其深远的现实意义,预期会带来巨大的社会效益和经济效益。
进一步,脂质体是由磷脂和胆固醇构成的磷脂双分子层闭合形成的小室状结构,具有与生物膜非常相似的性质,生物相容性好,可提高药物的溶解度,且易实现产业化生产。目前,脂质体常规制备方法包括薄膜分散法、逆向蒸发法、溶剂注入法和喷雾干燥法。这些技术普遍存在微粒粒径和分布难以控制、得率较低、包封率和载药量不理想、有机溶剂残留量大、工艺条件影响药物活性等缺陷。
发明内容
本发明所要解决的第一个技术问题是针对现有技术而提供一种骨关节健康改善效果好的用于改善骨关节健康的口服脂质体组合物。
本发明所要解决的第二个技术问题是针对现有技术而提供一种骨关节健康改善效果好并具有降脂作用的用于改善骨关节健康的口服脂质体组合物。
本发明所要解决的第三个技术问题是针对现有技术而提供一种有效成分利用率高的用于改善骨关节健康的口服脂质体组合物。
本发明所要解决的第四个技术问题是针对现有技术而提供一种食用安全性高的用于改善骨关节健康的口服脂质体组合物。
本发明所要解决的第五个技术问题是针对现有技术缺陷而提供一种上述用于改善骨关节健康的口服脂质体组合物的制备方法。
本发明解决至少一个上述技术问题所采用的技术方案为:一种用于改善骨关节健康的口服脂质体组合物,其特征在于包括以下组分:
其中,非变性II型胶原蛋白通过直接促成软骨细胞产生二型胶原蛋白和蛋白多糖从而激活T-regulator,被非变性二型胶原蛋白激活的T-Regulator释放两种免疫调节细胞(分别为TGF-β和IL-10),能有益地改变免疫应答反应以及其他组织生化反应,进一步激活软骨细胞。
牡蛎提取物能促进大鼠肝糖原、肌糖原等能源物质的积累,保证大鼠运动期间较高的血糖水平及较好的运动能力。
橄榄果提取物能够引起血清中促炎细胞因子IL1β、IL6、IL8、IL12、TNFα水平的下降和导致抗炎细胞因子IL10的血清水平升高,具有明显的抗炎效果。
进一步,所述中药提取物为杜仲叶、肉桂、三七叶、青钱柳叶、淡竹叶、柳叶蜡梅、葛根的提取物的混合物,且上述物质的质量比为1~5:1~2:1~5:1~5:1~10:1~5:1~10。上述中药提取物含有多糖、黄酮等具有抗炎作用的活性成分,且生物利用率高。
进一步,所述中药提取物的制备方法包括以下步骤:
(a)常压沸水提取:将杜仲叶、肉桂、三七叶、青钱柳叶、淡竹叶、柳叶蜡梅、葛根按照一定质量比混合,投入提取容器中进行提取,加入10~20倍的纯化水,开启搅拌,加热升温保持其温度在98±2℃,加热1~2小时,过200目筛,提取两次,合并滤液;
(b)减压浓缩:将提取滤液进行减压浓缩,浓缩温度控制在60~72℃,真空度控制在-0.07~-0.09Mpa,相对密度控制在1.02~1.08之间,获得浸膏;
(c)喷雾干燥:将浸膏灭菌过滤后进行喷雾干燥,其中,进风温度为150~185℃,出口温度为80-95℃,上料速度为1.0~2.5L/min,获得所需的中药提取物。该制备方法由于采用微沸搅拌提取技术、低温真空浓缩技术以及喷雾干燥技术,完成了对中药有效成分的充分提取和保留,极大地降低了服用量。
进一步,所述小麦低聚肽的制备方法包括以下步骤:
(a)调浆:将小麦蛋白加适量纯化水,搅拌打浆10~50分钟后备用;
(b)酶解:将上述小麦蛋白浆加热至20~40℃,加入胰蛋白酶、碱性蛋白酶等复合酶,调节PH至7.5~11,水解时间为1~3h;
(c)灭酶:酶解结束后,调节PH至中性,加热至沸腾,保温10~20分钟后离心;
(d)膜过滤:离心液进行膜过滤,收集分子量小于4000的滤液;
(e)离子交换:过离子交换柱脱盐;
(f)减压浓缩:将提取滤液进行减压浓缩,浓缩温度控制在60~75℃,真空度控制在-0.07~-0.09Mpa,相对密度控制在1.03~1.08之间,获得浓缩液;
(g)喷雾干燥:将浓缩液经灭菌后进行喷雾干燥,其中,进风温度为150~175℃,出口温度为85-95℃,上料速度为2.0~2.5L/min,得到小麦低聚肽粉。小麦低聚肽粉含有人体所需的各种氨基酸,可以增强运动耐受力,补充小麦低聚肽有效促进大负荷运动训练或高原训练大鼠IGF-1分泌,对减缓大负荷运动导致的骨骼肌蛋白减少有重要作用。
进一步,所述软骨胶原蛋白肽的制备方法包括以下步骤:
(a)调浆:兔软骨加适量纯化水,粉碎,搅拌10~50分钟得蛋白浆,备用;
(b)酶解:将上述蛋白浆加热至38~42℃,加入胰蛋白酶,调节PH至9.5~10.5,水解时间为1~3h;
(c)灭酶:酶解结束后,调节PH至中性,加热至沸腾,保温10~20分钟,离心;
(d)膜过滤:离心液进行膜过滤,收集分子量小于3000的滤液。
(e)离子交换:过离子交换柱脱盐。
(f)减压浓缩:将提取滤液进行减压浓缩,浓缩温度控制在55~65℃,真空度控制在-0.07~-0.09Mpa,相对密度控制在1.05~1.08之间,获得浓缩液;
(g)喷雾干燥:将浓缩液灭菌后喷雾干燥,其中,进风温度150~175℃,出口温度85-95℃,上料速度2.0~2.5L/min,得到软骨胶原蛋白肽粉。
软骨胶原蛋白肽含有生物活性的硫酸软骨素,具有减轻关节疼痛、提升腿部力量的作用,无任何毒副作用,不产生依赖或者上瘾性,具有明确的缓解关节疼痛、提升腿部力量的作用。
进一步,上述牡蛎低聚肽选用太平洋牡蛎肉,经酶膜耦合技术,核心是蛋白质规模化定向酶切和小分子组分分离浓缩技术:
(1)基于蛋白质组学定向酶切设计,准确把控酶切位点、有效控制分子量、定向获取目标肽段;
(2)优化多级复合纳滤膜处理技术,主生产单元多通道运行,对牡蛎肽成分进行精细分离控制,将目标产物定向富集并进行多级精制;
(3)针对牡蛎原料特性,选择专用酶制剂及精制技术,解决牡蛎蛋白质原料分离提纯、小分子蛋白靶向降解、产品均一稳定、降低蛋白致敏性、风味提升等核心问题。
进一步,所述橄榄果提取物的制备方法包括以下步骤:
(a)清洗去杂:将新鲜橄榄果清洗干净,去除果蒂等杂质备用;
(b)真空冷冻干燥:将上述清洗后的橄榄果切片,将水果切片进行真空冷冻干燥;
(c)低温粉碎:将干燥结束后的水果冻干片投入进行低温粉碎,所得果粉要求80%过10目筛;
(d)超纯水提取:将橄榄果粉投入提取容器中,加入10~25倍体积的超纯水,开启搅拌,加热升温保持其温度在98±2℃,过200目筛,提取两次,提取时间1-2小时,合并滤液;
(e)减压浓缩:将提取滤液进行减压浓缩,浓缩温度控制在55~65℃,真空度控制在-0.07~-0.09Mpa,相对密度控制在1.03~1.07之间,获得浓缩液;
(f)喷雾干燥:将浓缩液喷雾干燥,工艺参数为进风温度150~175℃,出口温度85-95℃,上料速度2.0~2.5L/min,得到橄榄果提取物。橄榄果提取物含有丰富的羟基酪醇,具有抗氧化、抗炎等功效。
上述透明质酸钠是一种葡聚糖醛酸,是人体内一种固有的成分,广泛存在于胎盘、羊水、晶状体、关节软骨、皮肤真皮层等组织,对关节有很好的润滑作用,有效缓解关节磨损,减轻疼痛。
上述植物固醇是植物性油脂的非皂化物,以大豆和油菜籽油饼为原料,或者来自制造米糠油时的非皂化物,经提取、精制后得到的制品。植物固醇在肠道内可以与胆固醇竞争,减少胆固醇吸收,有效地降低高脂血症患者血液中的总胆固醇和低密度脂蛋白胆固醇含量,而不影响血液中高密度脂蛋白胆固醇,对高血脂患者有很好的降脂效果。
上述大豆磷脂是从生产大豆油的副产品中提取、精制而成,组成成分主要有卵磷脂、脑磷脂、肌醇磷脂、磷脂酸及其他磷脂,为白色至浅棕色的固体粉末。
为进一步解决上述第五个技术问题所采用的技术方案为:一种如上所述的用于改善骨关节健康的口服脂质体组合物的制备方法,其特征在于包括以下步骤:
按上述质量份数将上述中药提取物、软骨胶原蛋白肽、小麦低聚肽、橄榄果提取物、透明质酸钠、非变性II型胶原蛋白、牡蛎低聚肽、大豆磷脂、植物甾醇经超临界流体强化溶液快速分散技术制备所需的口服脂质体组合物。超临界流体强化溶液快速分散技术作为一种新型微粒制备方法,操作条件温和,所得产物颗粒细微,颗粒大小分布均匀,包封率高,载药量大,且无溶剂残留等优点。
进一步,开启超临界流体强化溶液快速分散设备,沉淀釜的温度和压力达到设定值,调节压力直至体系达到平衡;将上述质量份数的大豆磷脂以及植物甾醇加至一定量的食用无水乙醇中溶解完全,获得的溶液通过高压恒流泵由喷嘴输入到经过预稳定的沉淀釜内;
待溶液输入完毕后,立即关闭恒流泵,继续通入CO2除尽釜内的剩余溶剂,关闭 CO2输入阀,打开排气阀,排出沉淀釜内的气体,待釜内压力降至0MPa时,打开沉淀釜并收集沉淀物,得到脂质体前体,脂质体前体与剩余原料以及其他辅料混合均匀、分装、包装即得所需的口服脂质体组合物。该口服脂质体组合物可为软饮料、片剂、硬胶囊剂、颗粒剂或固体饮料中的任意一种剂型。
与现有技术相比,本发明的优点在于:本发明综合考虑中老年人群牙齿易松动脱落、胃肠吸收能力下降、三高比例高等情况,利用口服脂质体作用时间长、刺激性小、依从性好、服用方便等优点,同时进一步提高了中药提取物的水溶性差和生物利用度,提升了组合物的综合药效。其中,以植物甾醇代替传统的胆固醇,利用植物甾醇在肠道内可以与胆固醇竞争的性质,减少胆固醇吸收,有效地降低血液中的总胆固醇和低密度脂蛋白胆固醇含量,而不影响血液中高密度脂蛋白胆固醇,对高血脂患者有很好的降脂效果。各种组分合理搭配、适口性好,不添加防腐剂、人工色素、合成香精香料,药食同源,具有良好的改善骨关节健康的功效。
本发明采用超临界流体强化溶液快速分散技术来制备口服脂质体组合物,该技术操作条件温和,所得产物颗粒细微,颗粒大小分布均匀,包封率高,载药量大,且无溶剂残留,本发明的制备方法最大程度地保留了药物、食材的主要功效成分,服用量显著下降的同时也极大地提高了药物的生物利用度,患者依从性好,达到快速改善骨关节炎症状的目的。
具体实施方式
以下结合实施例对本发明作进一步详细描述。
实施例1:
中药提取物的制备过程如下:
(a)常压沸水提取:将杜仲叶、肉桂、三七叶、青钱柳叶、淡竹叶、柳叶蜡梅、葛根按照质量比1~5:1~2:1~5:1~5:1~10:1~5:1~10混合,投入提取罐中进行提取,加入纯化水,开启搅拌,加热升温保持其温度在98±2℃,提取两次,第一次加水20倍,提取 2小时,第二次加水10倍,提取1小时,200目筛过滤,合并滤液;
(b)减压浓缩:将提取滤液进行减压浓缩,浓缩温度控制在65℃,真空度控制在 -0.07~-0.09Mpa,相对密度控制在1.02~1.05,获得浸膏;
(c)喷雾干燥:将浸膏灭菌过滤后喷雾干燥,工艺参数为进风温度165℃,出口温度88℃,上料速度2.2L/min,得到提取物粉。
进一步,中药提取物由于采用了微沸搅拌提取技术、低温真空浓缩技术、喷雾干燥技术,完成了对中药有效成分的充分提取和保留,极大地降低了服用量。
实施例2:小麦低聚肽的制备
小麦低聚肽的制备过程如下:
(a)调浆:将小麦蛋白(谷朊粉)加适量纯化水,搅拌打浆30分钟,备用;
(b)酶解:将上述小麦蛋白浆加热至40℃,加入胰蛋白酶、碱性蛋白酶等复合酶,分别调节PH至8、10,水解时间为3h;
(c)灭酶:酶解结束后,调节PH至中性,加热至沸腾,保温20分钟。
(d)离心:蝶式或管式离心机离心。
(e)膜过滤:离心液进行膜过滤,收集分子量小于4000的滤液。
(f)离子交换:过离子交换柱脱盐。
(g)减压浓缩:将提取滤液进行减压浓缩,浓缩温度控制在70℃,真空度控制在 -0.08~-0.09Mpa,相对密度控制在1.03~1.05,获得浓缩液;
(h)喷雾干燥:将浓缩液经UHT灭菌后喷雾干燥,工艺参数为进风温度165℃,出口温度85℃,上料速度2.0L/min,得到小麦低聚肽粉。
实施例3:软骨胶原蛋白肽的制备
(a)调浆:兔软骨加适量纯化水,粉碎,搅拌10-50分钟,备用;
(b)酶解:将上述蛋白浆加热至48-52℃,依次加入胰蛋白酶、木瓜蛋白酶,分别调节PH至7.5-8.0、5.5-6.5,水解时间为1~3h;
(c)灭酶:酶解结束后,调节PH至中性,加热至沸腾,保温10-20分钟。
(d)离心:蝶式或管式离心机离心。
(e)膜过滤:离心液进行膜过滤,收集分子量小于3000的滤液。
(f)离子交换:过离子交换柱脱盐。
(g)减压浓缩:将提取滤液进行减压浓缩,浓缩温度控制在55~65℃,真空度控制在-0.07~-0.09Mpa,相对密度控制在1.03~1.07之间,获得浓缩液;
(h)喷雾干燥:将浓缩液经UHT灭菌后喷雾干燥,工艺参数为进风温度150~175℃,出口温度85-95℃,上料速度2.0~2.5L/min,得到软骨胶原蛋白肽粉。
实施例4:橄榄果提取物的制备
橄榄果提取物的制备过程如下:
(a)清洗去杂:将新鲜橄榄果使用纯化水充分清洗干净,去除果蒂等杂质备用;
(b)真空冷冻干燥:将上述水果切片,平均厚度控制在4mm,将水果切片投入真空冷冻干燥设备中进行干燥,参数设定为预冻速率0.4℃/min,预冻初始温度-40℃,预冻终点温度-70℃,干燥室压力45pa,加热板温度42℃,干燥时间为22h;
(c)低温粉碎:将干燥结束后的水果冻干片投入低温粉碎机中进行低温粉碎,所得果粉要求80%过10目筛。
(d)超纯水提取:将橄榄果粉投入提取罐中进行提取,加入10~25倍的超纯水,开启搅拌,加热升温保持其温度在98±2℃,提取两次,第一次加水20倍,提取2小时,第二次加水15倍,提取1小时,200目筛过滤,合并滤液。
(e)减压浓缩:将提取滤液进行减压浓缩,浓缩温度控制在55~65℃,真空度控制在-0.07~-0.09Mpa,相对密度控制在1.03~1.07之间,获得浓缩液;
(f)喷雾干燥:将浓缩液喷雾干燥,工艺参数为进风温度150~175℃,出口温度85-95℃,上料速度2.0~2.5L/min,得到橄榄果提取物。
实施例5:具有改善骨关节健康功能的口服脂质体组合物的制备
实施例5.1:
称取3份透明质酸钠、4份非变性II型胶原蛋白(北京盛美诺生物技术有限公司,非变性II型胶原蛋白含量≥15%)、3份牡蛎肽(浙江海氏生物科技有限公司,低聚肽(以干基计)含量≥15%)、3份植物甾醇、3份大豆磷脂,5份中药提取物(实施例1制备)、 1份橄榄果提取物(实施例4制备)、5份软骨胶原蛋白肽(实施例3制备)、5份小麦低聚肽(实施例2制备)等原料备用。
开启超临界流体强化溶液快速分散设备(SFE121-50-01型超临界CO2制粒装置,南通华兴石油仪器有限公司),沉淀釜的温度和压力达到设定值,调节压力直至体系达到平衡。将大豆磷脂以及植物甾醇加至10份食用无水乙醇中溶解完全,获得的溶液通过高压恒流泵由喷嘴输入到经过预稳定的沉淀釜内。
待溶液输入完毕后,立即关闭恒流泵,继续通入CO2除尽釜内的剩余溶剂。关闭 CO2输入阀,打开排气阀,排出沉淀釜内的气体,待釜内压力降至0MPa时,打开沉淀釜并收集沉淀物,得到脂质体前体。向剩余原料加入10份纯化水、2份猕猴桃汁搅拌溶解,经高压均质机均质,与脂质体前体进行混合水化,灭菌、包装即得口服脂质体饮品。
实施例5.2:
称取2份透明质酸钠、5份非变性II型胶原蛋白、6份牡蛎肽、4份植物甾醇、3 份大豆磷脂、4份中药提取物(实施例1制备)、1份橄榄果提取物(实施例4制备)、4 份软骨胶原蛋白肽(实施例3制备)、4份小麦低聚肽(实施例2制备)等原料备用。
开启超临界流体强化溶液快速分散设备,沉淀釜的温度和压力达到设定值,调节压力直至体系达到平衡。将大豆磷脂以及植物甾醇加至12份食用无水乙醇中溶解完全,获得的溶液通过高压恒流泵由喷嘴输入到经过预稳定的沉淀釜内。
待溶液输入完毕后,立即关闭恒流泵,继续通入CO2除尽釜内的剩余溶剂。关闭 CO2输入阀,打开排气阀,排出沉淀釜内的气体,待釜内压力降至0MPa时,打开沉淀釜并收集沉淀物,得到脂质体前体。脂质体前体与剩余原料、2份草莓粉于混合机中混合均匀、分装、包装即得口服脂质体固体饮料。
实施例5.3:
称取3份透明质酸钠、3份非变性II型胶原蛋白、5份牡蛎肽、3份植物甾醇、1 份大豆磷脂、5份中药提取物(实施例1制备)、2份橄榄果提取物(实施例4制备)、5 份软骨胶原蛋白肽(实施例3制备)、3份小麦低聚肽(实施例2制备)等原料备用。
开启超临界流体强化溶液快速分散设备,沉淀釜的温度和压力达到设定值,调节压力直至体系达到平衡。将大豆磷脂、植物甾醇,加至10份食用无水乙醇中溶解完全,上述溶液通过高压恒流泵由喷嘴输入到经过预稳定的沉淀釜内。
待溶液输入完毕后,立即关闭恒流泵,继续通入CO2除尽釜内的剩余溶剂。关闭 CO2输入阀,打开排气阀,排出沉淀釜内的气体,待釜内压力降至0MPa时,打开沉淀釜并收集沉淀物,得到脂质体前体。脂质体前体与剩余原料、5份草莓粉、1份硬脂酸镁、1份二氧化硅于混合机中混合均匀、压片、包装即得口服脂质体片。
实施例6:人群试食试验
通过临床症状改善情况来评定效果:
显著:膝关节疼痛及肿胀现象消失,活动不受限;
有效:膝关节疼痛及肿胀现象改善,活动轻微受限;
无效:膝关节疼痛及肿胀现象仍然存在,活动明显受限。
有效率=(显著+有效)/总例数×100%。通过发放调查问卷,征集40名具有膝关节疼痛症状志愿者(年龄45-70岁、男性20人,女性20人)试用实施例6制备样品。
随机分为4组,每组10人,男女各半,其中对照组1组,试验组3组,对照组服用安慰剂饮品,试验组分别服用实施例5.1、5.2、5.3制备的样品,每日服用1袋(实施例5.1或实施例5.2)或6片(实施例5.3),连续服用30天,记录4组患者膝功能恢复情况,包括膝关节疼痛缓解时间、肿胀缓解时间及恢复正常活动时间等。
分别在服用前及服用后4周运用骨性关节炎指数评分量表进行评估:无疼痛(0分)、轻微疼痛(3分及以下)、中度疼痛(4~6分)、重度疼痛(7~10分)。经对调查问卷分析,服用实施例5.1-5.3试验组,疼痛状况减轻者占比分别为44.3%、50.6%、56.5%,对照组为25.8%。
Claims (8)
2.如权利要求1所述的用于改善骨关节健康的口服脂质体组合物,其特征在于,所述中药提取物为杜仲叶、肉桂、三七叶、青钱柳叶、淡竹叶、柳叶蜡梅、葛根的提取物的混合物,各提取物的原料质量比为1~5:1~2:1~5:1~5:1~10:1~5:1~10。
3.如权利要求2所述的用于改善骨关节健康的口服脂质体组合物,其特征在于,所述中药提取物的制备方法包括以下步骤:
(a)常压沸水提取:将杜仲叶、肉桂、三七叶、青钱柳叶、淡竹叶、柳叶蜡梅、葛根按照上述质量比混合,投入提取容器中进行提取,加入10~20倍的纯化水,开启搅拌,加热升温保持其温度在98±2℃,提取两次,过200目筛,合并滤液;
(b)减压浓缩:将提取滤液进行减压浓缩,浓缩温度控制在60~72℃,真空度控制在-0.07~-0.09Mpa,相对密度控制在1.02~1.08之间,获得浸膏;
(c)喷雾干燥:将浸膏灭菌过滤后进行喷雾干燥,其中,进风温度为150~185℃,出口温度为80-95℃,上料速度为1.0~2.5L/min,获得所需的中药提取物。
4.如权利要求1所述的用于改善骨关节健康的口服脂质体组合物,其特征在于,所述小麦低聚肽的制备方法包括以下步骤:
(a)调浆:将小麦蛋白加适量纯化水,搅拌打浆10~50分钟后备用;
(b)酶解:将上述小麦蛋白浆加热至20~40℃,加入胰蛋白酶、碱性蛋白酶等复合酶,调节PH至7.5~11,水解时间为1~3h;
(c)灭酶:酶解结束后,调节PH至中性,加热至沸腾,保温10~20分钟后离心;
(d)膜过滤:离心液进行膜过滤,收集分子量小于4000的滤液;
(e)离子交换:过离子交换柱脱盐;
(f)减压浓缩:将提取滤液进行减压浓缩,浓缩温度控制在60~75℃,真空度控制在-0.07~-0.09Mpa,相对密度控制在1.03~1.08之间,获得浓缩液;
(g)喷雾干燥:将浓缩液经灭菌后进行喷雾干燥,其中,进风温度为150~175℃,出口温度为85-95℃,上料速度为2.0~2.5L/min,得到小麦低聚肽粉。
5.如权利要求1所述的用于改善骨关节健康的口服脂质体组合物,其特征在于,所述软骨胶原蛋白肽的制备方法包括以下步骤:
(a)调浆:兔软骨加适量纯化水,粉碎,搅拌10~50分钟得蛋白浆,备用;
(b)酶解:将上述蛋白浆加热至38~42℃,加入胰蛋白酶,调节PH至9.5~10.5,水解时间为1~3h;
(c)灭酶:酶解结束后,调节PH至中性,加热至沸腾,保温10~20分钟,离心;
(d)膜过滤:离心液进行膜过滤,收集分子量小于3000的滤液。
(e)离子交换:过离子交换柱脱盐。
(f)减压浓缩:将提取滤液进行减压浓缩,浓缩温度控制在55~65℃,真空度控制在-0.07~-0.09Mpa,相对密度控制在1.05~1.08之间,获得浓缩液;
(g)喷雾干燥:将浓缩液灭菌后喷雾干燥,其中,进风温度150~175℃,出口温度85-95℃,上料速度2.0~2.5L/min,得到软骨胶原蛋白肽粉。
6.如权利要求1所述的用于改善骨关节健康的口服脂质体组合物,其特征在于,所述橄榄果提取物的制备方法包括以下步骤:
(a)清洗去杂:将新鲜橄榄果清洗干净,去除果蒂等杂质备用;
(b)真空冷冻干燥:将上述清洗后的橄榄果切片,将水果切片进行真空冷冻干燥;
(c)低温粉碎:将干燥结束后的水果冻干片投入进行低温粉碎,所得果粉要求80%过10目筛;
(d)超纯水提取:将橄榄果粉投入提取容器中,加入10~25倍体积的超纯水,开启搅拌,加热升温保持其温度在98±2℃,提取两次,200目筛过滤,合并滤液;
(e)减压浓缩:将提取滤液进行减压浓缩,浓缩温度控制在55~65℃,真空度控制在-0.07~-0.09Mpa,相对密度控制在1.03~1.07之间,获得浓缩液;
(f)喷雾干燥:将浓缩液喷雾干燥,工艺参数为进风温度150~175℃,出口温度85-95℃,上料速度2.0~2.5L/min,得到橄榄果提取物。
7.一种如权利要求1~6任一项所述的用于改善骨关节健康的口服脂质体组合物的制备方法,其特征在于包括以下步骤:
按上述质量份数将上述中药提取物、软骨胶原蛋白肽、小麦低聚肽、橄榄果提取物、透明质酸钠、非变性II型胶原蛋白、牡蛎低聚肽、大豆磷脂、植物甾醇经超临界流体强化溶液快速分散技术制备所需的口服脂质体组合物。
8.如权利要求7所述的用于改善骨关节健康的口服脂质体组合物的制备方法,其特征在于包括以下步骤:
开启超临界流体强化溶液快速分散设备,沉淀釜的温度和压力达到设定值,调节压力直至体系达到平衡;将上述质量份数的大豆磷脂以及植物甾醇加至一定量的食用无水乙醇中溶解完全,获得的溶液通过高压恒流泵由喷嘴输入到经过预稳定的沉淀釜内;
待溶液输入完毕后,立即关闭恒流泵,继续通入CO2除尽釜内的剩余溶剂,关闭CO2输入阀,打开排气阀,排出沉淀釜内的气体,待釜内压力降至0MPa时,打开沉淀釜并收集沉淀物,得到脂质体前体,脂质体前体与剩余原料以及药学或食品上可接受的其他辅料混合均匀、分装、包装即得所需的口服脂质体组合物,该口服脂质体组合物可为软饮料、片剂、硬胶囊剂、颗粒剂或固体饮料中的任意一种剂型。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210293733.3A CN114601920A (zh) | 2022-03-23 | 2022-03-23 | 一种用于改善骨关节健康的口服脂质体组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210293733.3A CN114601920A (zh) | 2022-03-23 | 2022-03-23 | 一种用于改善骨关节健康的口服脂质体组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114601920A true CN114601920A (zh) | 2022-06-10 |
Family
ID=81864807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210293733.3A Pending CN114601920A (zh) | 2022-03-23 | 2022-03-23 | 一种用于改善骨关节健康的口服脂质体组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114601920A (zh) |
Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1579366A (zh) * | 2004-05-17 | 2005-02-16 | 刘贤英 | 一种中药生物祛皱嫩肤化妆品及其制备工艺 |
WO2015149177A1 (en) * | 2014-04-01 | 2015-10-08 | Klox Technologies Inc. | Tissue filler compositions and methods of use |
CN105617358A (zh) * | 2015-12-29 | 2016-06-01 | 广州市戴菊科技发展有限公司 | 一种具有抗肿瘤功能的医用食品及其制备方法 |
WO2016198932A2 (en) * | 2015-05-06 | 2016-12-15 | Uti Limited Partnership | Nanoparticle compositions for sustained therapy |
CN106619877A (zh) * | 2017-02-15 | 2017-05-10 | 王维义 | 一种用于改善骨关节痛的组合物及其制备方法 |
CN108030088A (zh) * | 2017-10-26 | 2018-05-15 | 武汉轻工大学 | 一种蛋白修饰植物甾醇脂质体粉末的制备方法 |
CN108261361A (zh) * | 2018-02-09 | 2018-07-10 | 广东科玮生物技术股份有限公司 | 一种含有细胞生长因子的祛痘修复膏及其制备方法 |
CN108721161A (zh) * | 2018-05-16 | 2018-11-02 | 珀莱雅化妆品股份有限公司 | 一种育发组合物及其脂质体制备方法 |
CN109463489A (zh) * | 2019-01-11 | 2019-03-15 | 中南林业科技大学 | 一种米糠蛋白茶饮料及其制备方法 |
CN111467481A (zh) * | 2020-05-08 | 2020-07-31 | 江苏新中基生物科技有限公司 | 一种改善和/或预防骨关节炎的组合物及其应用 |
CN111568783A (zh) * | 2020-06-23 | 2020-08-25 | 昆仑技术研究(广州)有限公司 | 一种白番茄提取物脂质体冻干粉的制备方法及其应用 |
CN112159442A (zh) * | 2020-09-28 | 2021-01-01 | 燕山大学 | 一种纳米樱桃花色苷制备方法 |
CN112315821A (zh) * | 2020-12-03 | 2021-02-05 | 暨南大学 | 一种水解蛋白脂质体及其制备方法与应用 |
CN112807416A (zh) * | 2021-01-18 | 2021-05-18 | 宁波御坊堂生物科技有限公司 | 具有改善骨关节健康功能的中药骨肽组合物及其制备方法 |
CN112999158A (zh) * | 2021-03-03 | 2021-06-22 | 江西省科学院生物资源研究所 | 一种普利醇纳米脂质体的制备方法及其应用 |
CN113576939A (zh) * | 2021-08-03 | 2021-11-02 | 北京清大赛尔生物科技有限公司 | 一种生物精华多肽组合物及其脂质体纳米化的制备方法与应用 |
CN113876639A (zh) * | 2021-11-12 | 2022-01-04 | 湖北省麦诗特生物科技有限公司 | 一种含有提高皮肤弹性脂质体的面霜组合物及其制备方法 |
CN113893203A (zh) * | 2021-11-23 | 2022-01-07 | 湖北省麦诗特生物科技有限公司 | 一种含有抗衰老功效脂质体的面霜组合物及其制备方法和应用 |
CN113967192A (zh) * | 2021-11-09 | 2022-01-25 | 陕西海斯夫生物工程有限公司 | 一种用于加速伤口愈合的药物组合物、它们的制备方法与用途 |
-
2022
- 2022-03-23 CN CN202210293733.3A patent/CN114601920A/zh active Pending
Patent Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1579366A (zh) * | 2004-05-17 | 2005-02-16 | 刘贤英 | 一种中药生物祛皱嫩肤化妆品及其制备工艺 |
WO2015149177A1 (en) * | 2014-04-01 | 2015-10-08 | Klox Technologies Inc. | Tissue filler compositions and methods of use |
CN106413766A (zh) * | 2014-04-01 | 2017-02-15 | 克洛克斯科技公司 | 组织填料组合物及使用方法 |
WO2016198932A2 (en) * | 2015-05-06 | 2016-12-15 | Uti Limited Partnership | Nanoparticle compositions for sustained therapy |
CN107847582A (zh) * | 2015-05-06 | 2018-03-27 | 优迪有限合伙公司 | 用于持续疗法的纳米颗粒组合物 |
CN105617358A (zh) * | 2015-12-29 | 2016-06-01 | 广州市戴菊科技发展有限公司 | 一种具有抗肿瘤功能的医用食品及其制备方法 |
CN106619877A (zh) * | 2017-02-15 | 2017-05-10 | 王维义 | 一种用于改善骨关节痛的组合物及其制备方法 |
CN108030088A (zh) * | 2017-10-26 | 2018-05-15 | 武汉轻工大学 | 一种蛋白修饰植物甾醇脂质体粉末的制备方法 |
CN108261361A (zh) * | 2018-02-09 | 2018-07-10 | 广东科玮生物技术股份有限公司 | 一种含有细胞生长因子的祛痘修复膏及其制备方法 |
CN108721161A (zh) * | 2018-05-16 | 2018-11-02 | 珀莱雅化妆品股份有限公司 | 一种育发组合物及其脂质体制备方法 |
CN109463489A (zh) * | 2019-01-11 | 2019-03-15 | 中南林业科技大学 | 一种米糠蛋白茶饮料及其制备方法 |
CN111467481A (zh) * | 2020-05-08 | 2020-07-31 | 江苏新中基生物科技有限公司 | 一种改善和/或预防骨关节炎的组合物及其应用 |
CN111568783A (zh) * | 2020-06-23 | 2020-08-25 | 昆仑技术研究(广州)有限公司 | 一种白番茄提取物脂质体冻干粉的制备方法及其应用 |
CN112159442A (zh) * | 2020-09-28 | 2021-01-01 | 燕山大学 | 一种纳米樱桃花色苷制备方法 |
CN112315821A (zh) * | 2020-12-03 | 2021-02-05 | 暨南大学 | 一种水解蛋白脂质体及其制备方法与应用 |
CN112807416A (zh) * | 2021-01-18 | 2021-05-18 | 宁波御坊堂生物科技有限公司 | 具有改善骨关节健康功能的中药骨肽组合物及其制备方法 |
CN112999158A (zh) * | 2021-03-03 | 2021-06-22 | 江西省科学院生物资源研究所 | 一种普利醇纳米脂质体的制备方法及其应用 |
CN113576939A (zh) * | 2021-08-03 | 2021-11-02 | 北京清大赛尔生物科技有限公司 | 一种生物精华多肽组合物及其脂质体纳米化的制备方法与应用 |
CN113967192A (zh) * | 2021-11-09 | 2022-01-25 | 陕西海斯夫生物工程有限公司 | 一种用于加速伤口愈合的药物组合物、它们的制备方法与用途 |
CN113876639A (zh) * | 2021-11-12 | 2022-01-04 | 湖北省麦诗特生物科技有限公司 | 一种含有提高皮肤弹性脂质体的面霜组合物及其制备方法 |
CN113893203A (zh) * | 2021-11-23 | 2022-01-07 | 湖北省麦诗特生物科技有限公司 | 一种含有抗衰老功效脂质体的面霜组合物及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR0126431B1 (ko) | 혈당강하 효과가 있는 건강식품 조성물 | |
CN107348521B (zh) | 具有改善胃肠道功能的中药复合肽组合物及其制备方法 | |
CN101612315A (zh) | 一种用于调整人体机能的中药复方制剂 | |
CN114403320A (zh) | 一种发酵乳杆菌及具有减肥功能的发酵饮品和制备方法 | |
CN108324921B (zh) | 一种具有祛除囊肿、保护胃粘膜功能的药物组合物及其制备方法 | |
CN112587648A (zh) | 一种防治糖尿病的苦瓜肽组合物及其制备方法 | |
CN102188486A (zh) | 一种防治脂肪肝的药物组合物及其制备方法 | |
CN114601920A (zh) | 一种用于改善骨关节健康的口服脂质体组合物及其制备方法 | |
KR102659842B1 (ko) | 차전자피 및 복합추출물을 포함하는 장 기능 개선 및 배변 촉진용 건강기능식품 조성물 및 이의 제조방법 | |
CN111870627A (zh) | 一种解酒制剂及其制备方法和用途 | |
CN114306544B (zh) | 一种降血糖组合物及制备方法 | |
CN107440114B (zh) | 一种具有抗pm2.5颗粒物功效的组合物 | |
CN105559078A (zh) | 一种具有补血功效的组合物及其制备方法 | |
CN107320569A (zh) | 一种平脂咀嚼片及其制备方法 | |
CN115120710A (zh) | 一种降血脂组合物及其制备方法和应用 | |
CN113925172A (zh) | 一种适用于儿童的大鲵肽营养组合物 | |
CN107375697B (zh) | 一种具有润肠通便的复方制剂及其制备方法和应用 | |
CN114404515B (zh) | 一种甲鱼胶囊 | |
CN110250516A (zh) | 一种具有缓解压力和增强免疫力的组合物及其制备方法 | |
CN119113077B (zh) | 一种植物成分降血糖组合物及其制备方法和应用 | |
CN115040572B (zh) | 一种天然促排油减肥组合物及其制备方法 | |
CN119054875A (zh) | 一种蛋白质与植物提取物组合的制备方法 | |
CN1280007A (zh) | 木耳调脂胶囊 | |
CN1099882C (zh) | 减肥药及其制作方法 | |
CN117599110A (zh) | 一种具有降血糖血脂、延缓衰老功能的发酵组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |